These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 16139828

  • 1. Associations of Fas (CD95), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), and biochemical manifestations in elderly persons.
    Choi JW.
    Clin Chim Acta; 2006 Mar; 365(1-2):113-8. PubMed ID: 16139828
    [Abstract] [Full Text] [Related]

  • 2. Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults.
    Choi JW.
    Ann Hematol; 2005 Oct; 84(11):728-33. PubMed ID: 16007425
    [Abstract] [Full Text] [Related]

  • 3. Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults.
    Choi JW, Song JS, Pai SH.
    Ann Clin Lab Sci; 2004 Oct; 34(4):400-4. PubMed ID: 15648780
    [Abstract] [Full Text] [Related]

  • 4. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J.
    J Am Coll Cardiol; 2005 Apr 05; 45(7):1018-24. PubMed ID: 15808757
    [Abstract] [Full Text] [Related]

  • 5. Involvement of tumor necrosis factor-alpha receptor 1 and tumor necrosis factor-related apoptosis-inducing ligand-(TRAIL) receptor-2/DR-5, but not Fas, in graft injury in live-donor liver transplantation.
    Tashiro H, Itamoto T, Ohdan H, Arihiro K, Tateaki Y, Nakahara H, Ochi M, Hino H, Mizunuma K, Hara H, Tokita D, Onoe T, Ishiyama K, Mitsuta H, Sugino K, Asahara T.
    Transpl Int; 2004 Nov 05; 17(10):626-33. PubMed ID: 15502938
    [Abstract] [Full Text] [Related]

  • 6. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M.
    Ann Rheum Dis; 2005 Jun 05; 64(6):854-8. PubMed ID: 15564310
    [Abstract] [Full Text] [Related]

  • 7. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N.
    Eur J Haematol; 2006 Jan 05; 76(1):64-74. PubMed ID: 16343273
    [Abstract] [Full Text] [Related]

  • 8. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.
    Hum Pathol; 2005 Oct 05; 36(10):1066-73. PubMed ID: 16226105
    [Abstract] [Full Text] [Related]

  • 9. [The expression of TRAIL, TRAIL-R (DR4, DcR1) and Fas-L in patients with ovarian cancer].
    Li CM, Peng ZL, Yang KX.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May 05; 36(3):341-3. PubMed ID: 15931863
    [Abstract] [Full Text] [Related]

  • 10. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I.
    J Clin Pathol; 2006 Jul 05; 59(7):716-20. PubMed ID: 16489180
    [Abstract] [Full Text] [Related]

  • 11. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A, Mantovani I, Tazzari PL, Grafone T, Martinelli G, Cocco L, Martelli AM.
    Int J Mol Med; 2005 Dec 15; 16(6):1041-8. PubMed ID: 16273284
    [Abstract] [Full Text] [Related]

  • 14. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S, Abraham P, Daniel HD, Ramakrishna BS, Sridharan G.
    J Clin Virol; 2005 Sep 15; 34(1):63-70. PubMed ID: 16087126
    [Abstract] [Full Text] [Related]

  • 15. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D, Réveiller M, Florin A, Blanchard C, Ruffion A, Devonec M, Benahmed M, Grataroli R.
    J Cell Physiol; 2006 Mar 15; 206(3):709-17. PubMed ID: 16245307
    [Abstract] [Full Text] [Related]

  • 16. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems.
    Walczak H, Krammer PH.
    Exp Cell Res; 2000 Apr 10; 256(1):58-66. PubMed ID: 10739652
    [No Abstract] [Full Text] [Related]

  • 17. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H, Narita K, Endo S.
    J Crit Care; 2001 Jun 10; 16(2):59-63. PubMed ID: 11481600
    [Abstract] [Full Text] [Related]

  • 18. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
    Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, Zielinski CC, Horvat R, Zeillinger R, Reinthaller A, Krainer M.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8585-91. PubMed ID: 16361541
    [Abstract] [Full Text] [Related]

  • 19. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
    Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B, Parent JL.
    Biochem Biophys Res Commun; 2005 Jul 22; 333(1):42-50. PubMed ID: 15936719
    [Abstract] [Full Text] [Related]

  • 20. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
    Begue B, Wajant H, Bambou JC, Dubuquoy L, Siegmund D, Beaulieu JF, Canioni D, Berrebi D, Brousse N, Desreumaux P, Schmitz J, Lentze MJ, Goulet O, Cerf-Bensussan N, Ruemmele FM.
    Gastroenterology; 2006 Jun 22; 130(7):1962-74. PubMed ID: 16762619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.